|
E-mail this page to a friend!
Alzheimer’s Memory Loss Possibly Restored by
Ampakine CX717
Company has begun enrollments for Phase II studies
Aug. 18, 2005 – Enrollment has begun for more Phase
II studies of Ampakine CX717, a drug that may improve memory function
for people with Alzheimer’s disease and address some of the underlying
causes of memory loss. The announcement from Cortex Pharmaceuticals says
drugs available today “simply treat symptoms.”
| |
Related Stories |
|
| |
Ispronicline Joins Effort to Find Alzheimer’s Cure
July 6, 2005 – There is a new kid on the block in
the mad race to find a cure for Alzheimer’s disease and dementia.
Ispronicline is now enrolling participants for a Phase II study after
clinical studies in which elderly people taking Ispronicline performed
better on memory and attention measures than those taking a placebo.
Read more...
Better Alzheimer’s Drugs May Come from Discovery
Anti-inflammatory function of Alzheimer's disease
drugs revealed
July 28, 2005 - The mechanism in anti-Alzheimer's
disease drugs that inhibits the production of a destructive,
inflammation-causing protein in the brain has been revealed by
researchers at the Hebrew University of Jerusalem, who say it could lead
to better treatment drugs.
Read
more...
Alzheimer’s Drug May Come from Discovery of
Molecules
July 23, 2005 - A team of scientists has discovered
three molecules –– from a search of 58,000 compounds –– that appear to
inhibit a key perpetrator of Alzheimer's disease. Each of the three
molecules protects the protein called "tau," which becomes hopelessly
tangled in the brains of patients with Alzheimer's. The finding is
promising news for the development of drugs for the disease.
Read more...
Click here to more news on
Alzheimer's |
|
Alzheimer's disease is the leading cause of
adult-onset dementia. It currently affects one in 10 senior citizens
over 65 and nearly half of the elderly over 85. The disorder is one of
the single greatest threats to the health of 77 million baby boomers and
is also one of their greatest fears of aging. In the US alone, the cost
of caring for individuals with Alzheimer's disease is estimated to be
$100 billion annually.
Cortex Pharmaceuticals is testing and developing a
second-generation class of pharmaceuticals classified as ampakine
compounds. Its lead compound, CX-717, is expected to treat the memory
and thinking disorders associated with Mild Cognitive Impairment, and
Alzheimer's disease as well as other disorders.
It is believed that loss of connections between
brain cells is responsible for memory loss. Ampakine compounds are said
to increase the signal strength at those connections.
Ampakines are designed to compensate for
deterioration of AMPA-receptor mediated brain activity in patients with
Alzheimer's and other disorders. Ampakines may also increase the amount
of certain growth factors in the brain, which, in turn, may help treat
the underlying causes of conditions like Alzheimer's disease.
"We believe our drugs can be disease modifying
therapies in contrast to the currently available symptomatic
treatments," says Dr. Roger Stoll, the CEO of Cortex Pharmaceuticals.
Alzheimer's disease is a gradually progressive
brain disorder that causes memory loss, cognitive dysfunction,
behavioral disturbances, and loss of the ability to take care of daily
activities. Though the disease progresses at different rates in
different people, in its severe stages most sufferers require total care
for their needs.
Cortex Pharmaceuticals recently announced that it
began enrollment in the second and third AMPAKINE(R) CX717 Phase IIa
studies: one in Attention Deficit Hyperactivity Disorder (ADHD) and the
other in mild to moderate Alzheimer's disease (AD).
In another study of ampakines, the U.S. Defense
Sciences Office said that a research team at Wake Forest University is
verifying and extending preliminary data demonstrating that the novel
class of medicines known as "Ampakines" is protective against cognitive
deficits associated with sleep deprivation. “It is envisioned that
Ampakines may provide an alternative to current stimulant medications
used by pilots,” they said.
For more information, visit the Website –
Click Here
Click to More Senior News on the
Front Page
Copyright: SeniorJournal.com |
